NCT05934045

Brief Summary

The objective of thE project is to determine, whether circRNAs could be used as circulating prognostic and/or predictive biomarkers of ALK+ ALCL resistance to treatment and whether they can be exploited as therapeutic targets.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2023

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2023

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

June 23, 2023

Completed
13 days until next milestone

First Posted

Study publicly available on registry

July 6, 2023

Completed
2.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

July 6, 2023

Status Verified

July 1, 2023

Enrollment Period

5 months

First QC Date

June 23, 2023

Last Update Submit

July 3, 2023

Conditions

ALK-Positive Anaplastic Large Cell Lymphoma

Keywords

cancer

Outcome Measures

Primary Outcomes (1)

  • Number of participants with relapse and circulating circRNA

    RNAseq analysis

    1 year after the end of treatment

Study Arms (1)

ALCL patient samples (serum)

serum collected at diagnosis, during treatment and/or at relapse

Biological: RNAseq

Interventions

RNAseqBIOLOGICAL

there is no intervention done.

ALCL patient samples (serum)

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patient at diagnosis of ALK+ ALCL, patient at the time of relapse for ALK+ ALCL, patient without ALK+ ALCL

You may qualify if:

  • patient at diagnosis of ALK+ ALCL
  • patient at the time of relapse for ALK+ ALCL
  • patient without ALK+ ALCL

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

IUCT-Oncopole University Hospital

Toulouse, 31500, France

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum

MeSH Terms

Conditions

Neoplasms

Interventions

Base Sequence

Intervention Hierarchy (Ancestors)

Molecular StructureBiochemical PhenomenaChemical PhenomenaGenetic StructuresGenetic Phenomena

Study Officials

  • Laurence Lamant

    University Hospital, Toulouse

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 23, 2023

First Posted

July 6, 2023

Study Start

January 1, 2023

Primary Completion

June 1, 2023

Study Completion

December 31, 2025

Last Updated

July 6, 2023

Record last verified: 2023-07

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)